JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2013, 62(6):243-248

Physiological factors with impact on the drug behaviour in the gastrointestinal tract

Aleš Franc1, Kateřina Dvořáčková1,*, Martina Kejdušová1, Roman Goněc2
1 Department of Pharmaceutics, Faculty of Pharmacy, Veterinary and Pharmaceutical University Brno, Brno, Czech Republic
2 Pharmacy, Masaryk Memorial Cancer Institute, Brno, Czech Republic

Orally administered drugs are passed through the gastrointestinal tract (GIT), which influences their next metabolism in the body. In the case of systemic administration, the drug is released from the dosage form, is dissolved and eventually absorbed. The residual amount is excreted in the faeces. The main factors influencing administered drugs are particularly pH, passage time, solubilizers or the oxido-reductive potential in different parts of the GIT. These factors are directly related to the release, absorption and stability of drugs. They can be used for simulation of the GIT environment in vitro and for the overall design of the dosage form in vivo. Because some literature data are not given in context and sometimes they are contradictory, this paper summarizes elementary values of the above-mentioned physiological parameters in the form of a review.

Keywords: drug; digestion; absorption; pH; GIT; motility; digestive enzymes

Received: September 13, 2013; Accepted: October 17, 2013; Published: June 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Franc A, Dvořáčková K, Kejdušová M, Goněc R. Physiological factors with impact on the drug behaviour in the gastrointestinal tract. Čes. slov. farm. 2013;62(6):243-248.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Goyal P., Kaur H., Jawanda M. K., Verma S., Parhar S. Salivary pH and dental caries in diabetes mellitus. Int. J. Oral. Max. Pathol. 2012; 4, 13-16.
    2. Mitra A., Kesisoglou F. Impaired drug absorption due to high stomach ph: a review of strategies for mitigation of such effect to enable pharmaceutical product development. http://pubs.acs.org/doi/ipdf/10.1021/mp400256h (22. 7. 20013).
    3. Dvořáčková K., Bautzová T., Rabišková M. Dissolution study in the evaluation of oral preparations with controlled drug release. Chem. Listy 2011; 105, 50-54.
    4. McConnell E. L., Fadda H. M., Basit A. W. Gut instincts: explorations in intestinal physiology and drug delivery. Int. J. Pharm. 2008; 364, 213-226. Go to original source... Go to PubMed...
    5. Trojan S. Lékařská fyziologie, 4. vyd. Praha: Grada Publishing 2003.
    6. Komárek P., Rabišková M., et al. Technologie léků: galenika. 3. vyd. Praha: Galén 2006.
    7. McCormick T. J., Gibson A. B., Diana F. J. Development and validation of a dissolution method for warfarin sodium and aspirin combination tablets. J. Pharmaceut. Biomed. 1997; 15, 1881-1891. Go to original source... Go to PubMed...
    8. Dissolution testing of immediate release solid oral dosage forms: Guidance for Industry. CDER 1997. http://www.fda.gov (4. 9. 2013).
    9. Immediate release solid oral dosage forms scale-up and postapproval changes: chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation. CDER. 1995. http://www.fda.gov (4. 9. 2013).
    10. Pilbrant A., Cederberg C. Development of an oral formulation of omeprazole. Scand. J. Gastroentero. 1985; 20, 113-120. Go to original source... Go to PubMed...
    11. Siepmanna F., Siepmanna J., Waltherb M., MacRaeb R. J., Bodmeier R. Polymer blends for controlled release coatings. J. Control. Release 2008; 125, 1-15. Go to original source... Go to PubMed...
    12. Dvořáčková K. Drug release from oral matrix tablets containing hypromelose. Chem. Listy 2009; 103, 66-72.
    13. Tenovuo J. O. Human saliva: clinical chemistry and microbiology. Boca Raton, Fla.: CRC Press 1989.
    14. Ménard D. Development of human intestinal and gastric enzymes. Acta Paediatr. 1994; 83, 1-6. Go to original source... Go to PubMed...
    15. Marschall S., Patterson C. Principles of molecular medicine. 2. vyd. NJ: Humana Press, 2006; 542-590.
    16. Franc A., Vetchý D., Smilková L., Rabišková M., Kratochvíl B. Lipophilic formulations for increasing bioavailability of poorly water-soluble drugs. Chem. Listy 2012; 106, 3-9.
    17. Singh S., Rama Rao K. V., Venugopal K., Manikandan R. Alteration in dissolution characteristics of gelatin-containing formulations: a review of the problem, test methods, and solutions. Pharm. Technol. 2002; 26, 36-58.
    18. Růžicka D., Kiss F., Hájek E., Sládek T., Martínek A., Buriánek I., Novotný J., Seménkova L., Hanák A. Tablets with controlled release of dilthiazemium chloride. Lachema, a.s., CS19890005635, priorita 10. 4. 1989.
    19. Heinicke R. M., Ito T., McCarthy L., Yokoyama M. Effect of bromelain on clinical laboratory tests after oral administration. Jpn. Heart J. 1971; 12, 517-527. Go to original source... Go to PubMed...
    20. Carey M. C., Small D. M., Bliss A. C. Lipid digestion and absorption. Annu. Rev. Physiol. 1983; 45, 651-677. Go to original source... Go to PubMed...
    21. Wen R. W., Thompson M. H., Hill M. J., Wilpart M., Mainguet P., Roberfroid A. M. The importance of the ratio of lithocholic to deoxycholic acid in large bowel carcinogenesis. Nutr. Cancer. 1987; 9, 67-71. Go to original source... Go to PubMed...
    22. Dahan A., Hoffman A. The effect of different lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats. Eur. J. Pharm. Biopharm. 2007; 67, 96-105. Go to original source... Go to PubMed...
    23. Rowe R. C., Sheskey J. P., Quinn M. E. Handbook of pharmaceutical excipients. 6. vyd. London: Pharmaceutical Press 2009.
    24. Gupta P. Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin. Tap Pharmaceutical Products Inc. US20010867353, priorita 29. 5. 2001.
    25. Rogers J. A., Anderson K. E. The potential of liposomes in oral drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 1998; 15, 421-480. Go to original source...
    26. Klein S. The use of biorelevant dissolution media to forecast the in vivo performance of a drug. AAPS J 2010; 12, 397-406. Go to original source... Go to PubMed...
    27. Guarner F., Malagelada J. R. Gut flora in health and disease. Lancet 2003; 360, 512-519. Go to original source... Go to PubMed...
    28. Sinha V. R., Kumria R. Microbially triggered drug delivery to the colon. Eur. J. Pharm Sci. 2003; 18, 3-18. Go to original source... Go to PubMed...
    29. Minko T. Drug targeting to the colon with lectins and neoglycoconjugates. Adv. Drug. Deliver. Rev. 2004; 491-509. Go to original source...
    30. Mooter G. B., Maris C., Samyn P., Augustijns P., Kinget R. Use of azo polymers for colon-specific drug delivery. J. Pharm. Sci. 1997; 12, 1321-1327. Go to original source... Go to PubMed...
    31. Yang L. Biorelevant dissolution testing of colon-specific delivery systems activated by colonic microflora. J. Control. Release 2007; 125, 77-86. Go to original source... Go to PubMed...
    32. Mercier G. T., Nehete P. N., Passeri M. F., Nehete B. N., Weaver E. A., Templeton N. S. Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. Vaccine. 2007; 25, 8687-8701. Go to original source... Go to PubMed...
    33. Press A. G., Hauptmann I. A., Hauptmann L., Fuchs B., Fuchs M., Ewe K., Ramadori G. Gastrointestinal pH profiles in patients with inflammatory bowel disease. Aliment. Pharm. Therap. 1998; 12, 673-678. Go to original source... Go to PubMed...
    34. Chawla G., Gupta P., Koradia V., Bansal A. K. Gastroretention: a means to address regional variability in intestinal drug absorption. Pharm. Tech. 2003; 27, 50-51.
    35. Zhao H., Cafiero S., Williams Z., Bynum K. C. Practical considerations for the development of a robust two-step dissolution test for enteric-coated immediate and extended release solid oral dosage formulations. Dissolut. Technol. 2011; 18, 6-10. Go to original source...
    36. Franc A., Sova P. Oral pharmaceutical composition for targeted transport of active substance into colon. Pliva-Lachema, a.s. CZ20040001167, priorita 12. 1. 2004.
    37. Hebden J. M., Gilchrist P. J., Perkins A. L., Wilson C. G., Spiller R. C. Stool water content and colonic drug absorption: contrasting effects of lactulose and codeine. Pharm. Res. 1999; 16, 1254-1259. Go to original source... Go to PubMed...
    38. Bhople A., Chandewar A., Sheiakh S. Ingole S., Deshmukh M., Pawar S. Formulation and development of mucoadhesive microcapsule for delivery of clarithromycin and omeprazole used against helicobacter pylori infection. AJPLS. 2012; 2, 27-48.
    39. Zhan J., Wang J., Zhang Y., Li W., Wu W. Method for preparing xanthan gum omeprazole intragastric retention floating sustained-release tablets. Jilin Institute of Chemical Technology. CN2012173347, priorita 3. 10. 2012.
    40. Rangasamy M., Ganesan P. G., Gummudavelly S., Ayyasamy B., Natesan S. Multiparticlate drug delivery systems: pellet & pelletization technique. DIT 2010; 5, 233-237.
    41. Dissolution Methods U. S. Food and Drug Administration Dissolution database - list of all drugs in the Database. http://www.accessdata.fda.gov/scripts/cder/dissolution/dsp_SearchResults_Dissolutions.cfm?PrintAll=1 (4. 9. 2013).
    42. Hall J. E. Guyton and Hall textbook of medical physiology. 12. vyd. Philadelphia, PA: Saunders Elsevier 2010.
    43. Silbernagl S., Despopoulos A. Atlas fyziologie člověka, 6. vyd. Praha: Grada Publishing 2004.
    44. Český lékopis 2009. 1. vyd. Praha: Grada Publishing 2009.

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.